Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ALNY heads into its October 29 earnings with a 10% monthly decline, a steady stream of target-price cuts, and a low-probability but non-trivial index deletion risk all competing for investors' attention.
The analyst picture is one of directional agreement but shrinking conviction. Every meaningful move in recent weeks has been a target reduction. Citigroup cut its target to $320 from $340 on Wednesday while keeping a Buy. JPMorgan trimmed to $369 from $375 at the end of September, also staying Overweight. RBC Capital came down to $345 from $350, maintaining Outperform. The consensus mean target is now $369.66, implying roughly 65% upside to the current $223.82 price. That gap is large enough to look less like confidence and more like targets that haven't caught down to the stock. The bull case centres on AMVUTTRA's broad ATTR-CM label in a market Alnylam estimates at roughly 500,000 patients globally, with the TTR franchise modelled to exceed $20.5 billion in peak annual revenue by 2040. The bear case is blunter: the DOJ subpoena on government price reporting, zilebesiran's uncertain path in hypertension, and a valuation that leans heavily on a late-decade revenue ramp. The EV/EBITDA multiple has contracted by 0.74 turns over the past month, and the price-to-book ratio has dropped by 1.27, both moving in the direction of re-rating rather than recovery.
Short positioning tells a more moderate story than the price action alone might suggest. Short interest has climbed 34% over the past month to 5.3% of the free float, a level worth watching but not extreme. Borrow is easy: cost to borrow has fallen 8% over the week to 0.38%, near the lowest level in six months, and availability is ample at 2,519%, meaning there are roughly 25 shares available to borrow for every one currently lent out. Nothing in the lending market points to squeeze pressure. Options positioning is similarly calm. The put/call ratio at 0.65 is almost exactly in line with its 20-day average of 0.645, a z-score of 0.31. With earnings two weeks out, there is no sign yet of options traders crowding into downside protection.
The institutional register is large and incrementally adding. Capital Research and Management holds 15.7% of shares, FMR LLC 10.7%, BlackRock 8.2%, and T. Rowe Price 5.1%, the latter having added nearly 500,000 shares as of the end of September. Wellington Management added over 465,000 shares in the same period. None of the 13D/G filings on record carry activist intent. The most notable development on the passive side is The Vanguard Group's latest 13G/A, filed in March, showing a reduction to zero percent of class from a prior 10.03%, though Vanguard Capital Management separately filed a fresh 13G in April at 5.35%. These are passive holder disclosures, not activist moves, and stakes can fall below 5% without a further filing. On the insider front, the only open-market trade in the past 90 days is a $399,000 sale by the EVP and Chief Legal Officer in early October, not under a 10b5-1 plan. Net insider flow on an open-market basis is modestly negative.
One peripheral risk worth noting is the Nasdaq-100 December Annual Review. ORTEX puts the probability of ALNY being deleted at 27%. The stock would need to fall a further 9.9% to $201.54 before the index exit line is triggered. At the current price that is comfortably out of range, and ORTEX's index model requires a move of negative 33.5% before the odds reach even money. Were a deletion to be announced, trackers would need to sell an estimated $2.6 billion worth of shares, equivalent to roughly 6.8 days of normal trading volume. Past comparable deletions from the Nasdaq-100 have produced a median move of negative 3.5% from announcement to effective date, with 79% of those names moving in the expected direction. The rank date is November 30, with any announcement due December 11.
Medicaid data from the Centers for Medicare and Medicaid Services offers colour on prescription trends. Medicaid dollars reimbursed were up 39% on Q1 last year, and Medicaid prescriptions rose 27% over the same period, covering Q1 2026. None of the ALNY datasets have been measured to lead the company's reported figures, so these readings describe reimbursement activity rather than foreshadow the print. Retail attention, as measured by Wikipedia views against ALNY's own 90-day history, is running well below average, with a z-score of negative 1.75, a detail more consistent with a stock that has been drifting lower than one that is actively on traders' radar.
The October 29 print is the next concrete event. After a 28% single-day drop following July results, the bar for execution is defined: investors will be watching whether AMVUTTRA volume trends and the gross-to-net trajectory on pricing hold up, and whether management has anything new to say on the DOJ inquiry.
See the live data behind this article on ORTEX.
Open ALNY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
